SAFETY AND TOLERABILITY OF SUBCUTANEOUS TRASTUZUMAB AS A TREATMENT IN PATIENTS WITH EARLY HER 2 POSITIVE BREAST CANCER : EXPERIENCE OF A CANCER CENTER IN PERU

被引：0
|
作者：
Otoya, Iris
Valdivieso, Natalia
Morante, Zaida
Castaneda, Carlos
Neciosup, Silvia
Calderon, Monica
Gomez, Henry
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 09期
关键词：
D O I：
10.1158/1538-7445.SABCS23-PO3-17-08
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PO3-17-08
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Subcutaneous trastuzumab: a review of its use in HER2-positive breast cancer
    Sanford, Mark
    TARGETED ONCOLOGY, 2014, 9 (01) : 85 - 94
  • [42] A multidisciplinary perspective on the subcutaneous administration of trastuzumab in HER2-positive breast cancer
    Dent, S.
    Ammendolea, C.
    Christofides, A.
    Edwards, S.
    Incekol, D.
    Pourmirza, B.
    Kfoury, S.
    Poirier, B.
    CURRENT ONCOLOGY, 2019, 26 (01) : E70 - E80
  • [43] Evaluating Trastuzumab in the treatment of HER2 positive breast cancer
    Jaques, Ryan
    Xu, Sam
    Matsakas, Antonios
    HISTOLOGY AND HISTOPATHOLOGY, 2020, 35 (10) : 1059 - 1075
  • [44] Safety of trastuzumab deruxtecan and radiation therapy in HER2-positive breast cancer patients
    Visani, Luca
    Ratosa, Ivica
    Ribnikar, Domen
    Becherini, Carlotta
    Bertini, Niccolo
    Bonaparte, Ilaria
    Stefanovski, Dimitar
    Dobnikar, Nika
    Desideri, Isacco
    Olmetto, Emanuela
    Mangoni, Monica
    Di Cataldo, Vanessa
    Peruzzi, Anna
    Mattioli, Chiara
    Cela, Doruntina
    Valzano, Marianna
    Salvestrini, Viola
    Scoccimarro, Erika
    Livi, Lorenzo
    Meattini, Icro
    RADIOTHERAPY AND ONCOLOGY, 2024, 194 : S691 - S692
  • [45] Neoadjuvant Trastuzumab and Pertuzumab for Early HER2-Positive Breast Cancer: A Real World Experience
    Hall, Benjamin James
    Bhojwani, Ajay Ashok
    Wong, Helen
    Law, Andrea
    Flint, Helen
    Ahmed, Eliyaz
    Innes, Helen
    Cliff, Joanne
    Malik, Zaf
    O'Hagan, Julie Elizabeth
    Hall, Allison
    Sripadam, Rajaram
    Tolan, Shaun
    Ali, Zulfiqar
    Hart, Clare
    Errington, Douglas
    Alam, Farida
    Giuliani, Rosa
    Mehta, Shaveta
    Khanduri, Sheena
    Thorp, Nicky
    Jackson, Richard
    Cicconi, Silvia
    Palmieri, Carlo
    BREAST JOURNAL, 2022, 2022
  • [46] Erratum to: Outcomes of trastuzumab therapy in HER2‑positive early breast cancer patients
    Hiroyasu Yamshiro
    Hiroji Iwata
    Norikazu Masuda
    Naohito Yamamoto
    Reiki Nishimura
    Shoichiro Ohtani
    Nobuaki Sato
    Masato Takahashi
    Takako Kamio
    Kosuke Yamazaki
    Tsuyoshi Saito
    Makoto Kato
    Tecchuu Lee
    Shinji Ohno
    Katsumasa Kuroi
    Toshimi Takano
    Masahiro Takada
    Shinji Yasuno
    Satoshi Morita
    Masakazu Toi
    International Journal of Clinical Oncology, 2015, 20 : 723 - 724
  • [47] Observational study on adjuvant trastuzumab in HER2-positive early breast cancer patients
    Mustacchi, G.
    Puglisi, F.
    Molino, A. M.
    Crivellari, D.
    Ghiotto, C.
    Ferro, A.
    Brunello, A.
    Saracchini, S.
    Turazza, M.
    Cretella, E.
    Iop, A.
    Malagoli, M.
    Stefani, M.
    FUTURE ONCOLOGY, 2015, 11 (10) : 1493 - 1500
  • [48] Optimising HER2-positive Breast Cancer Treatment: Insights on Subcutaneous Pertuzumab-trastuzumab Transition
    Surekha, S.
    Lamiyan, A. K.
    Khatri, P.
    Patil, A. N.
    CLINICAL ONCOLOGY, 2025, 41
  • [49] COST MINIMIZATION ANALYSIS OF TRASTUZUMAB SUBCUTANEOUS VERSUS INTRAVENOUS IN TREATMENT OF HER2-POSITIVE EARLY OR METASTATIC BREAST CANCER IN VIETNAM
    Nguyen, T.
    Tran, D.
    VALUE IN HEALTH, 2020, 23 : S130 - S131
  • [50] Trastuzumab and Vinorelbine in Early Stages of HER2-Positive Breast Cancer
    Ferrario, C.
    Wong, A.
    Gao, T.
    Bouganim, N.
    Aloyz, R.
    Panasci, L. C.
    JOURNAL OF CHEMOTHERAPY, 2011, 23 (01) : 32 - 35
12345